A. Menarini Pharma GmbH ist eine österreichische Tochtergesellschaft der Menarini Group/Florenz.
Lesen Sie die neuesten Nachrichten von der Menarini Gruppe.
A. Menarini Pharma GmbH is an Austrian subsidiary of the Menarini Group/Florence.
Read the latest news from the Menarini Group.
Anoro Ellipta is a combination of 2 long-acting bronchodilators (umeclidinium as a long-acting muscarinic antagonist, LAMA and vilanterol as a beta2-agonist, LABA) in the intuitive Ellipta inhaler. Anoro Ellipta is indicated for adult COPD patients as bronchodilator maintenance therapy for symptom relief.1
Anoro Ellipta is suitable for new initiations and/or conversions from LAMA or ICS/LABA or other dual bronchodilators.2
References: 1 Anoro Ellipta Drug information; 2 GOLD 2022 Report: Available from https://goldcopd.org/wp-content/uploads/2021/11/GOLD-REPORT-2022-v1.0-12Nov2021_WMV.pdf
AT-WEB-04-10-2021
Incruse Ellipta is a 24-hour bronchodilator in the intuitive Ellipta inhaler and contains umeclidinium as a LAMA (long-acting muscarinic antagonist). Incruse Ellipta is indicated for adult COPD patients in need of maintenance therapy for symptom relief.1
Incruse Ellipta is suitable for new appointments and/or conversions from short-acting bronchodilators or other LAMAs.2
References: 1 Incruse Ellipta Drug information; 2 GOLD 2022 Report: Available from https://goldcopd.org/wp-content/uploads/2021/11/GOLD-REPORT-2022-v1.0-12Nov2021_WMV.pdf
AT-WEB-05-10-2021
Relvar Ellipta is a once-daily ICS/LABA combination in the intuitive Ellipta inhaler that improves asthma control and reduces COPD exacerbations, both compared to standard therapy.1,2 The active ingredients are fluticasone furoate as an ICS (inhaled corticosteroid) and vilanterol as a LABA (beta2-agonist).3
Relvar Ellipta is suitable for asthma patients 12 years of age and older in whom a combination ICS/LABA is indicated. There are 2 strengths of Relvar Ellipta available for the treatment of asthma patients: Relvar Ellipta 92mcg/22mcg (green box) and Relvar Ellipta 184mcg/22mcg.
Relvar Ellipta is also approved for the treatment of adult COPD patients with FEV1 <70% and exacerbations despite bronchodilator therapy.3
For COPD patients, Relvar Ellipta 92mcg/22mcg strength (green box) is available.
References: 1 Woodcock A et al., Lancet 2017; 390:2247–2255; 2 Vestbo J et al., N Engl J Med 2016; 1253-1260; 3 Relvar Ellipta Drug information
AT-WEB-06-10-2021
Trelegy Ellipta is a 1-times-daily inhaled triple therapy (ICS/LAMA/LABA) for COPD patients in the intuitive Ellipta inhaler that reduces exacerbations and significantly improves lung function compared with dual combinations.1 The active ingredients included are fluticasone furoate as an ICS (inhaled corticosteroid), umeclidinium as a LAMA (muscarinic receptor antagonist), and vilanterol as a LABA (beta2-agonist).
Trelegy Ellipta is indicated for patients with moderate to severe COPD who are not adequately controlled with dual inhaled therapy (LAMA/LABA or ICS/LABA).2
References: 1 Lipson DA et al., N Engl J Med 2018; 378(18):1671-1680; 2 Trelegy Ellipta Drug information
AT-WEB-07-10-2021
Anoro, Incruse, Relvar and Ellipta are registered trademarks of the GlaxoSmithKline plc group of companies. Anoro Ellipta, Incruse Ellipta and Relvar Ellipta were developed in collaboration with Innoviva Inc.